MLH1 and colorectal neoplasm: However, MLH1 promoter methylation has been shown to be superior to BRAF as a negative predictor in colorectal tumours [72], and the main indicator of non-pathogenicity in endometrial tumours where BRAF V600E status has no predictive value at all [21].